Pros and cons of radiotherapy omission in elderly breast cancer patients following breast conservative surgery

Ícaro T. Carvalho1#, Ana C. P. Rezende1#, Renata J. C. Bernardo2

1Department of Radiation Oncology, Israeli Hospital Albert Einstein, São Paulo, Brazil; 2Clinical Fellow, Israeli Hospital Albert Einstein, São Paulo, Brazil

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Ícaro T. Carvalho. Department of Radiation Oncology, Israeli Hospital Albert Einstein, Rua Ruggero Fasano, S/N- Bloco A- 3º SS, 05653-120 São Paulo, Brazil. Email: icaro.carvalho@einstein.br.

Abstract: Breast cancer is a highly prevalent disease worldwide, with adjuvant radiation therapy (RT) being considered standard of care after breast-conserving surgery (BCS). Older patient population can present multiple running comorbidities and less aggressive tumor behavior, and the absolute impact of adjuvant RT on local control can be low. This article aims to review the available literature about the impact of adjuvant RT, discussing characteristics to identify lower risk cases, and advantages and disadvantages of the omission of adjuvant radiotherapy in this group.

Keywords: Breast; cancer; radiation omission

Submitted Jul 31, 2019. Accepted for publication Oct 23, 2019.
doi: 10.21037/tcr.2019.10.39
View this article at: http://dx.doi.org/10.21037/tcr.2019.10.39

Introduction

Breast cancer is a highly prevalent disease, with approximately 2.1 million diagnoses estimated worldwide in 2018 (1). Relative survival at 5 years suffers a great variation in the world, ranging from 80% or over in North America, Sweden, Japan, Finland, and Australia to less than 60% in Brazil and Slovakia, and below 40% in Algeria (2).

Since 1985, after the publication of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 trial, radiation therapy (RT) after breast-conserving surgery (BCS) is the standard of care for patients with early breast cancer, offering improved local control and survival (3).

After this publication, data from NSABP B-21, which included women with small tumors (≤1 cm) randomized to receive isolated tamoxifen (TAM), isolated RT, or TAM associated with radiation after lumpectomy, with no difference demonstrated in distant recurrence or overall survival (OS), but local recurrence (LR) rate with TAM alone were 16.5%, compared with 2.8% in the RT plus TAM group. Forty percent of these patients had unknown or negative estrogen receptors (ERs) tumors, with LR reduced in all subgroups (4).

Breast cancer incidence is higher among older patients, with its peak between 50 and 69 years. Patients older than 70 years of age represent 22% of in situ cases, and 31% of invasive cases (5). This elderly population affected by breast cancer usually have running multiple comorbidities and less aggressive tumor behavior (6-8), which can diminish not the relative advantage of adjuvant RT, but the absolute benefit in local control.

Adjuvant RT omission for invasive breast carcinoma

By the time of publication of NSABP B-21, data were already emerging suggesting that there may exist a favorable subgroup of patients in whom irradiation may
not provide meaningful overall benefit. One of the first randomized clinical trials (RCT) evaluating RT omission after lumpectomy was published in 2002 by Fisher et al. They evaluated the need for breast irradiation in node-negative women with invasive breast cancers of ≤1 cm, speculating that TAM could be as or more effective than RT in reducing the rate of ipsilateral breast tumor recurrence (IBTR), and by the thesis that both modalities could be more effective than either alone. After lumpectomy, 1,009 women at any age (only less than 20% older than 70 years old) were randomly assigned to TAM (n=336), RT and placebo (n=336), or RT and TAM (n=337). Cumulative incidence of IBTR through 8 years was 16.5% with TAM, 9.3% with RT and placebo, and 2.8% with RT and TAM. RT reduced IBTR below the level achieved with TAM alone, regardless of ER status. Distant treatment failures and OS were not significantly different among the groups. There was a significant reduction in contralateral breast cancer (CBC) when TAM was used (4,9).

Fyles and his Canadian group (10) reported in 2004 the results of their test that included female patients 50 years of age and older randomly assigned to receive TAM alone (383 women) vs. TAM plus breast irradiation (386 women) with median follow-up 5.6 years. In this study, women who did not receive radiotherapy had a significantly higher rate of local relapse at 5 years (7.7%) than those who received (0.6%), with no significant differences in rates of distant relapse, OS, or breast cancer death, even with TAM and mandatory free resection margins. However, we can argue that patient selection in this study included large tumors (up to 5 cm in diameter) and did not require a hormone receptor-positive (HRp) status. Considering these factors, another planned analysis, including only ER-positive (ERp) tumors with ≤2 cm, still showed a significant and clinically important reduction in the LR rate in the group receiving radiotherapy; 3.6% in the TAM plus RT group vs. 15.2% in the TAM only group after 8 years.

Considering age as an important risk factor, data from the Group B Cancer and Leukemia Study (CALGB) C9343 that evaluated only women over 70 was still. It included ERp tumors ≤2 cm (or those with unknown receptor status), comparing the efficacy of TAM plus RT vs. TAM alone. Early results in 2004 suggested that the omission of RT was safe. With a short average follow-up of only 5 years, the incidence of IBTR or regional nodal recurrence was 1% for those receiving TAM plus RT and 4% for patients receiving only TAM. There was no difference in survival, time to distant metastasis or maximum breast preservation rate (11).

Soulos et al. (12) analyzed Medicare data until 2007 and reported that the use of RT had little impact, only slightly reducing the risk in this population and that probably with long-term follow-up these results would not be sustained. A long-term analysis was published to address these concerns, with a median follow-up of 12.6 years. At 10 years, 98% of patients receiving TAM plus RT were free from local and regional recurrences, when compared to 90% of those receiving TAM. There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or OS between the two groups. Ten-year OS was 67% and 66% in the TAM plus RT and TAM groups, respectively (13).

Following the CALGB C9343 rational, the PRIME II study tested RT omission vs. TAM alone in a population older than 65 years old with low-risk features (HRp, axillary node-negative, T1–T2 up to 3 cm at the largest dimension, and clear margins; grade 3 tumor histology or lymphovascular invasion, but not both). Between Apr 16, 2003, and Dec 22, 2009, 1,326 women who had BCS and were receiving adjuvant endocrine treatment, were randomly assigned to either whole-breast RT or no RT. After a median follow-up of 5 years, IBTR was 1.3% in women assigned to whole-breast RT and 4.1% in those assigned to RT omission. No differences in OS, regional recurrence, distant metastases, CBCs, or new breast cancers were noted between groups (14).

As can be seen, several studies have suggested that possibly older women with small tumors that express ERs and will be treated with anti-hormone therapy are part of a favorable subgroup of patients where breast irradiation does not provide a relevant overall benefit. However, an important criticism to be made of PRIME II, CALGB C9343 and similar studies is that the ipsilateral breast recurrence rate in the radiation omission group is relatively high compared to the group of women receiving RT (15).

Also, regarding locoregional control, a meta-analysis with 2,387 patients evaluated data on axillary recurrences for older women after 5 years follow-up (13,14,16). The combination of adjuvant TAM plus RT reduced axillary recurrence rates when compared to the use of TAM alone [relative risk (RR): 0.28, 95% confidence interval (CI): 0.10–0.81, P=0.02; 2,287 patients] with a number needed to treat (NNT) of 116 to avoid one axillary recurrence in 5 years. When we evaluated the subgroup analysis of these two studies, we found that both had low proportions
of axillary lymph node dissection (ALND): PRIME II with 22% ALND and CALGB C9343 with 36%. In this subgroup the low proportion of ALND did not cause statistical difference in axillary recurrence rates with the association of RT (9).

Even with this statically difference in locoregional control, it has to be considered the real clinical benefit of the RT addition in a population of old patients with competing comorbidities. In the CALGB C9343 study, only 21 (6.7%) of 313 deaths were due to breast cancer, and in PRIME II, only 12 (13.5%) of 89 deaths were caused by the disease (12,17,18). Beyond that, all other endpoints (OS, distant metastases, CBCs, or new breast cancers) did not differ between the groups.

It’s interesting to note that despite the evidence of an acceptable low-risk of cancer mortality in a selected group, there’s a reluctance to de-escalate therapy. RT rate utilization modestly decreased following the publication of CALGB C9343. Many factors seem to be associated with the physician decision on omitting RT in elderly women. The strongest predictors are advanced patient age, high comorbidity score, and low-grade disease (19,20).

The literature assessing the impact of RT on quality of life in elderly patients is limited, as studies do not correlate its adverse effects with its impact on lifestyle. Older women may also face difficulties in accessing treatment, such as reduced mobility, transportation limitations, and other social supports that were not mentioned in these studies (21).

**Adjuvant RT omission for ductal in situ breast carcinoma (DCIS)**

DCIS consists of a neoplastic tumor confined to the ductal system of the breast, without evidence of invasion of the lamina propria. It is a precursor lesion to invasive ductal carcinoma.

There are at least 4 reported RCTs of surgery resection vs. surgical resection plus RT for DCIS (22-25), and one meta-analysis of these trials, which shows a risk reduction of ipsilateral breast event in 10 years by 15.2% (26).

Several studies have tried to identify patients with favorable tumor characteristics in whom maybe RT could be avoided because of low recurrence rates, and derived from that were created score systems and nomograms to stratify these patients. One of note is the Van Nuys Prognostic Index (27) a scoring system that uses pathologic characteristics as tumor size, tumor grade, presence or absence of necrosis and margins status to try to predict recurrence rates. Another tool that can be used to aid the decision to offer adjuvant RT is the Memorial Sloan Kettering Cancer Center online nomogram to predict LR for DCIS (28).

One of the goals of BCS is to offer a good cosmetic outcome. Adjuvant RT for DCIS has no impact on OS, only in local control, and avoiding irradiation can lead to higher taxes of mastectomy (29).

**Future and decision-making tools**

Throughout the last decade there has been a growing interesting on the evidences that early-stage breast cancer represents a heterogeneous group of diseases defined by unique molecular subtypes that should, in theory, be treated in a more personalized way. However, the focus attention has been on the systemic treatments and risk of distant disease. Recently, some aspects correlating the impact of subtype on LR has also been appreciated (30).

According to these concepts, some open studies are testing whether a subset of patients can actually have a sufficiently low-risk of regional local relapse (RLR) in the absence of RT that justifies omission after BCS. Part of these studies suggest that high-tech genomic assays may be useful in predicting the risk of RVL for women undergoing BCS. For example, researchers such as Mamounas et al. (31) demonstrated that the risk of RLR is highly associated with risk groups of 21 recurrence genes (Oncotype-DX) in ERp breast cancer TAM-treated patients with either node-positive or node-negative (32).

Some ongoing trials are committed to demonstrate the influence of molecular subtypes and their genomic assays on the locorregional recurrence (LRR) (Table 1). The IDEA study, led by the University of Michigan, is a multicenter prospective cohort aiming to test for RT omission after BCS. The population tested includes patients with stage I unifocal disease, HRp, HER2−, aged 50 to 69 years and with an Oncotype-DX recurrence score (RS) ≤18 (33). PRECISION is a study led by Dana Farber-Brigham and Women's Hospital, which included, in a prospective cohort, patients with stage I unifocal disease with ERp, ages 50 to 75 and a Prosign PAM50 score less than 40 (34). Another study is the EXPERT trial, which uses the PAM50-based Prosigna test as a baseline, recruiting women with biologically low-risk luminal A stage I breast cancer aged ≥50 years. The primary endpoint is LR after BCS at 10 years and they will be randomized to RT plus hormone therapy vs. hormone therapy alone (30,35).
As the results of most of these trials will not be available in the immediate future, nomograms can be used to guide the daily practice and shared decision with the patients. One of the most solid ones was designed at MD Anderson Cancer Center using Surveillance, Epidemiology, and End Results—Medicare data to identify 16,092 women age 66 to 79 years treated with BCS between 1992 and 2002. This useful tool predicts 5- and 10-year mastectomy free survival among older women with early breast cancer using readily available clinicopathologic factors and can aid individualized clinical decision making by estimating predicted benefit from RT (36,37).

Conclusions—pros and cons of RT omission

Old women with low-risk breast cancer is a group of patients with excellent prognoses. The question is what kind of adjuvant treatment after BCS will guarantee this excellent outcome with less physical, social, emotional and financial cost.

Potential advantages of avoiding adjuvant RT treatment are:
- Absence of radiation treatment related acute and chronic toxicities;
- Lower health care costs.
Potential disadvantages of avoiding adjuvant RT treatment are:
- Increased RR of local cancer recurrence and breast cancer mortality;
- Lower cosmetic outcome (bigger resection to achieve clear adequate margins, less local control can translate into more future mastectomies).

The key to avoid overtreatment in these women is to identify the very low-risk cases of in situ or invasive carcinomas, using biological, clinical and histological markers of low-risk, combined to an individualized evaluation of competing comorbidities, properly selecting patients who could be safely avoided WBRT following BCS.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Vincent Vinh-Hung and Nam P Nguyen) for the series “Radiotherapy for Breast Cancer in Advanced Age” published in Translational Cancer Research. The article has undergone external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.10.39). The series “Radiotherapy for Breast Cancer in Advanced Age” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. International Agency for Research on Cancer. Latest global cancer data: cancer burden rises to 18.1 million
new cases and 9.6 million cancer deaths in 2018. Available online: https://www.who.int/cancer/PRGlobocanFinal.pdf
2. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008;9:730-56.
3. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.
4. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002;20:4141-9.
5. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, 2017. Available online: https://www.cancer.org/content/dam/cancer.org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf
6. Fish EB, Chapman JA, Link MA. Competing causes of death for primary breast cancer. Ann Surg Oncol 1998;5:368-75.
7. Diab SG, Elleidge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-6.
8. Pierga JY, Girre V, Laurence V, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004;13:369-75.
9. Chesney TR, Yin JX, Rajaee N, et al. Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: a systematic review and meta-analysis. Radiother Oncol 2017;123:1-9.
10. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963-70.
11. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-7.
12. Soulsos PR, Yu JB, Roberts KB, et al. Assessing the impact of a cooperative group trial on breast cancer care in the medicare population. J Clin Oncol 2012;30:1601-7.
13. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382-7.
14. Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015;16:266-73.
15. Hughes KS, Schnaper LA. Can older women with early breast cancer avoid radiation? Lancet Oncol 2015;16:235-7.
16. Smith IE, Ross GM. Breast radiotherapy after lumpectomy--no longer always necessary. N Engl J Med 2004;351:1021-3.
17. Bellon JR. Personalized radiation oncology for breast cancer: the new frontier. J Clin Oncol 2015;33:1998-2000.
18. Marcadis AR, Marti J. Overuse of radiation therapy (RT) in elderly women with breast cancer: the influence of access to care. Ann Surg Oncol 2019;26:S70.
19. Rhieu BH, Rajagopalan MS, Sukumvanich P, et al. Patterns of care for omission of radiation therapy for elderly women with early-stage breast cancer receiving hormonal therapy. Pract Radiat Oncol 2015;5:e267-73.
20. Peppercorn J, Jimenez R. Breaking up is hard to do: omission of radiation therapy for select women aged >70 years with breast cancer. Int J Radiat Oncol Biol Phys 2017;98:918-21.
21. Williams LJ, Kunkler IH, King CC, et al. A randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trial. Health Technol Assess 2011;15:i-xi, 1-57.
22. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001;28:400-18.
23. Donker M, Litière S, Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31:4054-9.
24. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
25. Wärnberg F, Garmo H, Emdin S, et al. Effect of radiotherapy after breast-conserving surgery for ductal
carcinoma in situ: 20 years follow-up in the randomized SwedCIS trial. J Clin Oncol 2014;32:3613-8.

26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010;2010:162-77.

27. de Mascarel I, Bonichon F, MacGrogan G, et al. Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations. Breast Cancer Res Treat 2000;61:151-9.

28. Memorial Sloan Kettering Cancer Center. Breast cancer nomogram: ductal carcinoma in situ (DCIS) recurrence. Available online: http://nomograms.mskcc.org/Breast/DuctalCarcinomaInSituRecurrencePage.aspx

29. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy. Breast 2018;37:181-6.

30. Horton JK, Jagsi R, Woodward WA, et al. Breast cancer biology: clinical implications for breast radiation therapy. Int J Radiat Oncol Biol Phys 2018;100:23-37.

31. Mamounas EP, Liu Q, Paik S, et al. 21-gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst 2017. doi: 10.1093/jnci/djw259.

32. Fitzal F, Filipits M, Rudas M, et al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer 2015;112:1405-10.

33. The IDEA study (individualized decisions for endocrine therapy alone). Available online: https://clinicaltrials.gov/ct2/show/NCT02400190

34. The PRECISION trial (profiling early breast cancer for radiotherapy omission): a phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT02653755

35. EXamining PErsonalised radiation therapy for low-risk early breast cancer (EXPERT). Available online: https://clinicaltrials.gov/ct2/show/NCT02889874

36. Albert JM, Liu DD, Shen Y, et al. Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol 2012;30:2837-43.

37. Smith BD, Buchholz TA. Radiation treatments after breast-conserving therapy for elderly patients. J Clin Oncol 2013;31:2367-8.